Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited announced the cessation of certain securities, with 120,000 options lapsing due to unmet conditions and over 2 million options expiring without exercise. This development may impact the company’s financial strategy and investor relations, as it reflects on the company’s ability to meet certain operational milestones.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on developing innovative cellular medicines. The company specializes in regenerative medicine, aiming to treat a range of diseases through its proprietary mesenchymal lineage adult stem cell technology.
Average Trading Volume: 5,377,053
Technical Sentiment Signal: Buy
Current Market Cap: A$3.7B
Learn more about MSB stock on TipRanks’ Stock Analysis page.